Tim F. Greten, M.D.

Senior Investigator

Thoracic and Gastrointestinal Malignancies Branch


Building 10, Room 3B43
Bethesda, MD 20892



Research Topics

Dr. Greten combines his medical expertise in gastroenterology, hepatology and medical oncology with his research expertise in tumor immunology. His research can be best described by the three terms “liver”, “cancer “ and “immunology”. Dr. Greten and his team try to better understand how tumors in the liver interact with the immune system and he utilized this knowledge to develop better treatment options for patients with tumors of the GI tract. Dr. Greten is an expert on immune suppressor mechanisms occurring in patients with liver cancer (and murine models of liver cancer) such as regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSC). In 2016 he published a landmark study on the role of fatty liver disease and CD4 T cells in HCC in Nature. Dr. Greten is also principle investigator of a number of immunotherapy trials in patients with GI cancer.


Tim F. Greten, M.D., received his medical training at Christian Albrechts University in Kiel, Germany in 1993.  He did his internship in Munich followed by a 3-year postdoctoral fellowship at the Johns Hopkins University (Baltimore, Maryland), in the laboratory of Drew Pardoll and Liz Jaffee, where he initiated his work in the field of tumor immunology.  In 1999 Dr. Greten returned to Hannover Medical School, where he finished his training in Internal Medicine (2003), Medical Oncology (2004) and Gastroenterology (2007). He held an Associate Professor position in the Department of Gastroenterology, Hepatology and Endocrinology.  In February 2010 Dr. Greten joined CCR's Medical Oncology Branch as head of the Gastrointestinal Malignancy Section and was promoted as a tenured Senior Investigator in 2015.

Dr. Greten has published more than 150 peer-reviewed papers on basic tumor immunology, translational research studies in hepatocellular carcinoma (HCC) as well as on clinical trials in different gastrointestinal malignancies, including HCC. Currently, Dr. Greten serves on the Center of Excellence in Immunology Steering Committee and Center for Advanced Preclinical Research oversight committee. He is a Chairperson of the CCR Scientific Protocol Review. 

Selected Publications

  1. Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, Stroncek DF, Terabe M, Kapoor V, ElGindi M, Han M, Thornton AM, Zhang H, Egger M, Luo J, Felsher DW, McVicar DW, Weber A, Heikenwalder M, Greten TF. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016;531(7593):253-7.

  2. Eggert T, Wolter K, Ji J, Ma C, Yevsa T, Klotz S, Medina-Echeverz J, Longerich T, Forgues M, Reisinger F, Heikenwalder M, Wang XW, Zender L, Greten TF. Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression. Cancer Cell. 2016;30(4):533-547.

  3. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66(3):545-551.

  4. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, Greten TF, Korangy F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008;135(1):234-43.

  5. Kapanadze T, Gamrekelashvili J, Ma C, Chan C, Zhao F, Hewitt S, Zender L, Kapoor V, Felsher DW, Manns MP, Korangy F, Greten TF. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol. 2013;59(5):1007-13.

This page was last updated on May 18th, 2018